ALLMedicine™ Solitary Fibrous Tumor Center

Mar 1st, 2023 - A 73-year-old woman was referred for 68Ga-DOTATOC PET/CT staging of a grade 2 pancreatic neuroendocrine tumor, which showed the primary pancreatic tumor, liver metastases, one left pleural metastasis, and high uptake in a mass of the right triceps...

Feb 8th, 2023 - A case of dedifferentiated meningeal solitary fibrous tumor.|2023|Persons JE,Eschbacher KL,|

Feb 7th, 2023 - Although well known as a fusion partner in hematological malignancies, fusion genes involving the ABL proto-oncogene 1 (ABL1), mapping to chromosomal region 9q34.12, have only been anecdotally reported in five soft tissue tumors. These neoplasms h...

Feb 3rd, 2023 - The utility of molecular imaging in solitary fibrous tumors has not been fully established. We present a rare case of recurrent intranasal solitary fibrous tumor incidentally localized on 68 Ga-PSMA PET/CT scan, which turned out to be metabolicall...

Jan 21st, 2023 - Cervical Intramedullary Solitary Fibrous Tumor.|2023|Attia EM,Sharma S,Woodley-Cook J,Spears J,Munoz DG,|

Feb 1st, 2022 - To estimate the sample size for stratum 1 (SFT), a Simon's optimal 2-stage phase II design has been used, having considered the published response rate based on Choi criteria in SFT patients which correspond to 40% in monotherapy. For a design wit...

Nov 18th, 2021 - Cohorts 1-6: COHORT 1 - Dedifferentiated Chondrosarcoma (DDCS): For DDCS sample size is obtained for the primary endpoint of 6-month progression-free survival rate, estimated accrual 24 months. A 6-m PFSR of 40% will be considered not promising wh...

Nov 1st, 2021 - This is an Italian, non randomized, open label, multi center, investigator-initiated, Phase II, clinical study to explore the activity of eribulin in a population of patients with progressive, advanced (i.e. locally advanced or metastatic), molecu...

Nov 1st, 2021 - Patients with solitary fibrous tumor will be randomized to receive 6 cycles of trabectedin or doxorubicin plus dacarbazine. In case of progression or unacceptable toxicity while under the experimental treatment prior to the completion of the 6 cyc...

Sep 28th, 2021 - This is an investigator initiated, open label, prospective, non-randomized, phase II trial aimed at evaluating the activity of Axitinib in progressive VEGFR2 and/or PDGFRB positive advanced Solitary Fibrous Tumor (SFT) patients. Patients with a do...

Oct 6th, 2021 - Gary Schwartz, MD Chief, Melanoma and Sarcoma Service Memorial Sloan-Kettering Cancer Center The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody (cixutumumab) and an mTOR inhibitor (temsiro...

Apr 2nd, 2021 - Transcript: William D. Tap, MD: What about the other FDA-approved drug for general soft tissue sarcomas, except for liposarcomas, such as Votrient (pazopanib)? What role does that play? I also want to bring us to more of the targeted discussio...

Dec 5th, 2020 - William D. Tap, MD Although soft-tissue sarcoma (STS) is seldom diagnosed in adults, the development of several new therapies in recent years for patients with rare subtypes is energizing leaders in the field and underscoring the need for a multi...

Oct 29th, 2018 - Soft tissue sarcomas are rare mesenchymal tumors that comprise 1% of all malignancies. Synovial sarcoma accounts for 5% to 10% of adult soft tissue sarcomas and usually occurs in close association with joint capsules, tendon sheaths, and bursa in.

Oct 29th, 2018 - Soft tissue sarcomas are rare mesenchymal tumors that comprise 1% of all malignancies. Synovial sarcoma accounts for 5% to 10% of adult soft tissue sarcomas and usually occurs in close association with joint capsules, tendon sheaths, and bursa in.